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ABSTRACT
Objective: Pretrial community consultation (CC) is required for emergency research conducted under an
exception from informed consent (EFIC) in the United States. CC remains controversial and challenging, and
minimal data exist regarding the views of individuals enrolled in EFIC trials on this process. It is important to
know whether participants perceive CC to be meaningful and, if so, whom they believe should be consulted.
Methods: We conducted a secondary analysis of data from two studies interviewing patients and surrogates of
two recent EFIC trials (PEER-RAMPART and PEER-ProTECT). These interviews included similar open- and
closed-ended questions regarding participants’ views of the importance of CC, the rationale for their responses,
and their views regarding which populations should be included in consultation efforts. A template analytic
strategy was used for qualitative analysis of textual data, and descriptive statistics were tabulated to characterize
demographic data and instances of major themes.
Results: Ninety percent of participants perceived CC to be valuable. Participants’ reasons for finding CC
valuable clustered in two categories: 1) as a method of informing the public about the trial to be conducted and
2) as a way of obtaining input and feedback from the community. Participants cited the medical community (43%)
and individuals with a connection to the study condition (41%) as the most important groups to involve in
consultation efforts; only 5% suggested consulting the general public in the area where the research will be
conducted.
Conclusion: Participants in EFIC trials and their decision makers generally valued CC as a method of informing
and seeking input from the community. Participants felt that the most appropriate groups to consult were the
medical community and individuals with connections to the condition under study. Consultation efforts focused on
these two groups, rather than the general public, may be more efficient and more meaningful to individuals involved
in EFIC trials. These findings also reinforce the importance of the distinction between public disclosure and CC.
To facilitate research for emergent conditions, FDAand DHHS regulations allow an exception from
informed consent (EFIC).1 This is essential for studies
in which interventions must be delivered quickly,
patients are not fully capacitated, and surrogates are
unavailable. The EFIC regulations have several
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distinctive requirements, including the conduct of
community consultation (CC) prior to study approval
and initiation.2
The role of CC and best methods for doing it
remain controversial. It is widely perceived as a bar-
rier, particularly because CC can be time- and labor-
intensive.3,4 Additionally, CC can be performed with
different methods and participants. Ambiguities about
which methods (e.g., surveys or group meetings) or
participant groups should be used have bred heteroge-
neous approaches and uncertainty about the value of
the process.5
One of the goals of CC is to show respect for
enrolled subjects.1 However, limited data exist regard-
ing the perspectives of those enrolled in EFIC trials
on the CC process. Prior reports suggest that patients
and surrogates are generally in favor of CC, but have
not examined how they find it meaningful or valu-
able.6,7 Knowing the ways in which actual EFIC trial
participants perceive CC to be meaningful and whom
they believe should be consulted may help CC prac-
tices to be more efficient and effective in expressing
respect.
METHODS
We conducted a retrospective, secondary analysis of
data from two previously published interview studies
with patients and surrogates (for patients without
capacity to be interviewed) enrolled in EFIC
research.6,7
1. The Patients’ Experiences in Emergency Research
(PEER) study was an interview study of 61 EFIC-
enrolled patients (n = 24) and surrogates (n = 37)
from 5 sites in the Rapid Anticonvulsant Medica-
tion Prior to Arrival Trial (RAMPART), a double-
blind, randomized, controlled trial comparing intra-
venous lorazepam with intramuscular midazolam
in prehospital treatment of status epilepticus.6,8
2. The PEER-ProTECT study was an interview study
with similar design and included 74 EFIC-enrolled
patients (n = 28) and surrogates (n = 46) from 12
sites in the Progesterone for the Treatment of
Traumatic Brain Injury (ProTECT III) study, a
phase III, randomized, placebo-controlled trial of
progesterone in treatment of moderate and severe
traumatic brain injury.7,9
Interviews were conducted over the phone by
trained interviewers. Interview guides were cognitively
pretested. They were interactive and combined closed-
ended, Likert-scale questions as well as open-ended
questions to obtain quantitatively meaningful estimates
of participants’ views and in-depth information regard-
ing the reasons for these views. The interview guides
contained additional follow-up questions to assess par-
ticipant understanding and provide opportunities for
participants to ask clarifying questions. Primary
domains focused on participants’ experiences and
views of EFIC research and their attitudes toward
enrollment in the parent trial.
Participants were also asked specifically whether they
believed CC is important and, in an open-ended for-
mat, the reasons for their view and whom they
thought should be consulted. Phrasing of these ques-
tions in each study were similar (Data Supplement S1,
available as supporting information in the online ver-
sion of this paper, which is available at https://doi.
org/onlinelibrary.wiley.com/doi/10.1111/acem.13265/
full). Prior reports focused on participants’ attitudes
toward EFIC and inclusion in the respective trials.
This report combines the two data sets in a focused
analysis of responses to questions related to CC alone
(Data Supplement S1).
Informed consent was obtained from all participants.
Both studies were approved by institutional review
boards at Emory University and participating sites.
Data Management and Analysis
All interviews were transcribed verbatim. Qualitative
descriptive analysis was conducted using the
MAXQDA software package and a template analytic
method. Prior to textual analysis, a priori codes were
developed based on expected response categories from
the literature. Additional inductive codes were created
during analysis. Once it was determined that no new
themes were emerging (saturation), the codebook was
reviewed and approved by all authors as final and
then used to code all interviews. Coded instances of
major themes were reviewed by all authors to ensure
they reflected the same concept. Discrepancies were
resolved by consensus among all authors. Descriptive
statistics were tabulated for demographic data and
instances of major themes. Bivariate analysis (chi-
square tests for proportions) were conducted to
explore relationships between demographic data and
major themes.
During analysis, participants were identified who
demonstrated an explicit and fundamental misunder-
standing of the meaning and process of CC. These
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responses were reviewed by all authors. Those for
whom there was consensus regarding such misunder-
standing were excluded from further analysis.
RESULTS
Seventy-four PEER-ProTECT interviews and 61 PEER-
RAMPART interviews were analyzed. Of 135 total
respondents, five terminated the interview prior to CC
questions, and 21 were excluded due to clear misun-
derstanding of CC. The most prevalent misunder-
standing was a misperception that CC involved asking
community members to make real-time decisions
regarding trial enrollment for a particular individual.
Of 109 participants with analyzable responses, the
mean age was 47 years (range = 20–86 years), 66
(61%) were female, 59 (56%) were white, and 58
(53%) had at least some college education. Among
these participants, 98 (90%) considered CC to be
important, seven (6%) considered it unimportant, and
four (4%) were undecided.
Positive Responses to CC
Of the 98 participants who considered CC to be
important, 79 provided one or more reasons for this
response. These reasons focused on two distinct,
though not mutually exclusive, functions (Table 1):
CC as a method of informing the public: 30
participants. These participants felt CC would ful-
fill investigators’ obligation of transparency, facilitate
trust, and respect the public’s “right to know” what is
happening in their community (Table 1). Some also
mentioned that it may help prepare community mem-
bers emotionally and practically in the event they were
enrolled in the trial. Others suggested CC may help
public relations by helping bolster or maintain a posi-
tive perception of the hospitals or researchers in the
community.
CC as a method of obtaining feedback and
input from the community: 54 partici-
pants. Some participants felt community input
could be used by researchers to improve the study.
This view was particularly common among individuals
who advocated consulting local health professionals
and the individuals with connections to the study con-
dition (Table 1). Others focused more on allowing the
community to have an opportunity to exercise over-
sight by assessing whether a study is in the
community’s best interest and influencing whether the
study is approved.
Negative Responses to CC
Among the seven (6%) participants who did not
believe that CC is important, reasons included the
belief that community members are unqualified or do
not understand research sufficiently to provide mean-
ingful input on the study (Table 1). Some participants
were specifically concerned that uninformed individu-
als might object and prevent a needed trial from tak-
ing place.
Whom to Consult
Participants most frequently suggested that CC efforts
should involve healthcare professionals (44 [43%])
and individuals such as patients or family members
who have personal experience with the study condi-
tion (42 [41%]). Interestingly, 64% of African Ameri-
can participants suggested involvement of individuals
with connections to the study condition, compared to
Table 1
Supporting Quotes
Positive View of CC: 98 participants (90%)
1. CC as a method of informing the public
“I believe when they put studies together, people should have
access to the information that it is being done, but I don’t know if
you have to go around the community asking if it is alright to do
it.”—3–005
2. CC as a method of obtaining feedback and input from the
community
“As the director explained to me, they reached out to several
medical organization and community leadership groups that relate
directly to seizure patients. I believe this is a good move because
those organizations are more in touch with the demographics of
the patients in the area. It gives them a good chance to get a
cross section view of how such a study might affect that local
populous.”—4–009
Negative View of CC: 7 participants (6%)
“I don’t really know what the community members would have to
say about it . . . It doesn’t bother me that they do, I just think it’s
an unnecessary step.”—C256
Whom to Consult
Medical Community
“So when you say they ask community members . . . Maybe it
seems like they should ask more like people at a hospital . . . Um,
well I think that if somebody’s a community member doesn’t
mean they would know a lot about, you know, health. So I think it
would, I think instead of a community member maybe it should
be like the hospital staff or something.”—C204
Condition-related Community
“Because it’s not really, 99 percent of the people out there, it
would never be pertinent to them, you know. Unless you’ve been
there, I don’t think you can, either in patient or the medical field, I
don’t really see how you form a, make an informed decision
about it.”—C230
CC = community consultation.
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only 24% of white participants (p = 0.001). Other
groups less frequently mentioned included religious
communities (7 [7%]) and specific demographic
groups (i.e., the elderly, minorities; 22 [22%]). Twenty-
five respondents (25%) said they did not know whom
to consult. Only five participants (5%) suggested con-
sulting the general public.
DISCUSSION
This study provides novel insights regarding enrolled
patients’ and surrogates’ views of CC.6,7 Two key find-
ings have practical importance and implications for
researchers.
First, participants identified two populations as
most meaningful to consult: those with connections to
the study condition and health care professionals.
While the general public is often included in CC due
to prevalent interpretations of the regulatory require-
ment to involve the “community in which the research
will be conducted” as the geographic community, par-
ticipants did not prioritize this group. Some even
expressed concern that uninformed members of the
general public may derail meaningful research.
It is important to recognize that FDA guidance
does not require the involvement of the general pub-
lic or consider the geographic and condition-related
communities to be necessarily distinct.10 Moreover,
the guidance document explicitly states that health
care professionals at research sites may be considered
part of the geographic community.2 Thus, CC efforts
focusing on local health professionals and individuals
with connections to the condition under study may
satisfy regulatory requirements and align with the
preferences of enrolled patients. CC focused on
these two groups may also be more time- and
cost-efficient than methods designed to represent the
general public.10
Second, many participants attributed CC’s value to
its ability to inform the public about the study. Pre-
and posttrial public disclosure (PD), however, is a dis-
tinct regulatory requirement.1 Although some CC
activities serve dual purposes, ideal methods for
increasing awareness about a trial are likely different
from ideal methods for soliciting high-quality input
from relevant stakeholders. While FDA guidance, to
some extent, may blur the distinction between PD and
CC by including community notification as a goal of
CC, disaggregating these functions may help to pro-
mote efficiency and optimize both PD and CC.10
This study had two principal limitations. First, the
process of CC and the regulations of EFIC research
are difficult to understand, as evidenced by frequent
misunderstandings and the need to exclude responses
from 21 participants. Second, not everyone included
in the parent EFIC trials was represented in these
interview studies. It is possible those who declined
participation in these interview studies6,7 may have dif-
ferent views of CC and EFIC. However, as reported
previously, PEER populations were similar demograph-
ically to their parent trials.6,7
CONCLUSION
Patients and surrogates enrolled in two exception from
informed consent trials valued community consulta-
tion as a way to inform and obtain feedback from the
community. These findings underscore the importance
of appreciating the distinction between community
consultation and public disclosure and of designing
consultation efforts to maximize meaningful feedback.
Participants prioritized involvement of health care pro-
fessionals and individuals with a connection to the
condition under study. Community consultation activi-
ties targeting these two groups, rather than the general
public, appear most consistent with the preferences of
trial participants and may improve consultation effi-
ciency while satisfying regulatory requirements.
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